Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MBOT
STRONG SELLMicrobot Medical Inc. · Healthcare · United States · $115M · Avg Vol: $1M/d
COMPANY DESCRIPTION
Microbot Medical Inc. is a medical device company developing disposable, remote-controlled micro-robotic systems for various endovascular and minimally invasive procedures. Its patented Liberty™ Robotic System aims to enhance precision and safety, providing a differentiated offering in the growing medical robotics market. The company is a niche innovator focused on disrupting traditional catheter-based interventions with its advanced micro-robotic technology.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — | — | 3.5M | 10.6M | — |
| EPS | -1.59 | -0.21 | -0.18 | -0.21 | -0.29 | — | -0.27 | -0.28 | -0.30 | — |
| Shares | 7.1M | 67.2M | 67.2M | 67.2M | 67.2M | +844.8% | 67.2M | — | — | — |
| Debt | 0.7M | 0.5M | 0.2M | 0.1M | 0.9M | 6.2% | 0.9M | — | — | — |
| Equity | 14.4M | 7.3M | 4.5M | 3.5M | 77.6M | 52.4% | — | — | — | — |
| Op CF | -9.4M | -11.5M | -8.5M | -8.8M | -13.0M | — | -15.2M | — | — | — |
| Inv CF | 3.2M | -3.8M | 2.0M | 1.5M | -72.4M | — | — | — | — | — |
| Fin CF | 0 | 4.3M | 6.6M | 7.9M | 86.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MBOT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MBOT | Microbot Medical Inc.(you) | $115M | 18 | STRONG SELL |
| KRMD | KORU Medical Systems, Inc. | $176M | 25 | SELL |
| DXR | Daxor Corporation | $61M | 44 | HOLD |
| OSUR | OraSure Technologies, Inc. | $273M | 47 | HOLD |
| KMTS | Kestra Medical Technologies, Ltd. | $1.2B | 21 | SELL |
| SMTI | Sanara MedTech Inc. | $234M | 58 | HOLD |
| PLSE | Pulse Biosciences, Inc. | $2.1B | 22 | SELL |
| EMBC | Embecta Corp. | $195M | 73 | BUY |
| ANGO | AngioDynamics, Inc. | $562M | 56 | HOLD |
| AZTA | Azenta, Inc. | $1.3B | 44 | HOLD |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%